These factors govern the basic principles upon which case selection is based, but even so, the basic consideration is not whether late-effects will be' proven to arise, but whether, if they do arise, they arise with a frequency. which makes 1311 therapy unjustifiable. If after 20 years-and the answer will be available within the'next few years -the incidence of carcinoma or leukaemia is of the order of only o. I % of cases treated, and present indications are that it will be much less than this, then 131I therapy will be the treatment of choice. (Fig. i) . Of the 500 patients 53 had had a previous partial thyroidectomy, the majority of them being in the 26% of patients below the age of 45 years. It can be seen then that because thyrotoxicosis is now recognized as a disease which affects older people to a very much greater extent than was previously appreciated, it is inevitable that very many patients will qualify for 131I therapy if the currently recognized indications for treatment are accepted.
Management of Patients
The majority of thyrotoxic patients can safely be given '-"I without any preliminary drug preparation, and this is in fact the usual procedure. It is essential that initial tracer measurements be made with 131I, not only to confirm the diagnosis and ensure that there is in fact thyroid gland avidity for the isotope, but also, in some clinics, to provide data upon which the size of the therapeutic dose is assessed.
If Summary.
We now have available in 1311 an agent which is almost universally available, which is .free of proven risk, which can be effective in all cases .of thyrotoxicosis, and which can achieve results in many patients which would not be feasible with any other form of treatment. Its role in the treatment of thyroid cancer is very limited, but it may become the dominant therapeutic aid for the control of one of the commonest endocrine disorders, thyrotoxicosis.
